Work

A Novel PRKAR1A::MET Fusion Dramatic Response to Crizotinib in a Patient with Unresectable Lung Cancer

Year: 2022

Type: article

Abstract: Clinical Practice Points •This report demonstrated a significant clinical benefit from first-line treatment of crizotinib in a patient with unresectable lung cancer with novel PRKAR1A::MET gene fusion. •After disease progress resulted from discontinued therapy, the patient still achieved clinical benefit from second-line monotherapy of crizotinib. •This finding provided insight to perform the clinical trials to assess the efficacy and rationale of first-line or second line treatment to patients with unresectable lung cancer carrying MET fusion.

Source: Clinical Lung Cancer

DOI: 10.1016/j.cllc.2022.10.001

Authors: Yang Yang, Yanxiang Zhang, Dandan Zhao, Xiaoli Li, Tonghui Ma

Institutions: Harbin Medical University, Third Affiliated Hospital of Harbin Medical University

Language: English

Topic: Lung Cancer Treatments and Mutations

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: hybrid

Estimated APC paid: $2,630